The cognitive footprint of medication: A review of cognitive assessments in clinical trials.
clinical trials
dizziness
polypharmacy
psychometric
somnolence
Journal
Journal of clinical pharmacy and therapeutics
ISSN: 1365-2710
Titre abrégé: J Clin Pharm Ther
Pays: England
ID NLM: 8704308
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
15
01
2020
revised:
09
03
2020
accepted:
06
04
2020
pubmed:
28
4
2020
medline:
13
4
2021
entrez:
28
4
2020
Statut:
ppublish
Résumé
Polypharmacy is common, and many medications have cognitive side effects. Such effects can be transient and subside when the drug in question is discontinued or can be long-lasting with effects present for years afterwards. Although formal assessment of cognition is feasible and often undertaken in neuropsychiatric trials, these effects are usually neglected in the evaluation of any non-neuropsychiatric health intervention. Medication effects can be assessed within a cognitive footprint framework, to account for the magnitude and the duration of cognitive side effects, with some likely to have a greater and more lasting effect than others. Adverse event reporting suggests that many medications may be indirectly associated with cognitive effects, for example due to headaches, somnolence and 'dizziness'; however, inferring causation from adverse event reporting can be problematic. In order to better understand the impact of investigational drug and concomitant medications effect on cognition, it would be essential to ensure cognition is prioritized in drug development evaluation. It is suggested that simple instruments that can be easily incorporated into existing trial designs are used to assess the cognitive footprint of medication. We present an overview of existing measures of cognition that can be integrated into drug trials in order to provide a cognitive footprint. Like quality of life testing, such tests should be administered as a standard throughout the key assessment stages of the design of the trial to ensure that any effects on this equally important outcome are also documented. Furthermore, employing routine cognition testing may also enable researchers to identify unanticipated beneficial and non-beneficial effects on cognition. Provision of such a cognitive footprint profile of drugs may provide the necessary evidence to enable decision-makers to make informed decisions on risk-benefit analysis that can subsequently make trade-offs between different drug regimens.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
874-880Informations de copyright
© 2020 The Authors. Journal of Clinical Pharmacy and Therapeutics published by John Wiley & Sons Ltd.
Références
Wang CH, Wang LS, Zhu N. Cholinesterase inhibitors and non-steroidal anti-inflammatory drugs as Alzheimer's disease therapies: an updated umbrella review of systematic reviews and meta-analyses. Eur Rev Med Pharmacol Sci. 2016;20(22):4801-4817.
Bromley R, Weston J, Adab N, et al.Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Cochrane Database of Systematic Reviews, 2014. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010236.pub2/abstract.
Baker C. Medicine statistics: GP prescribing by constituency. 2015;2016.
Rawle MJ, Cooper R, Kuh D, Richards M. Associations between polypharmacy and cognitive and physical capability: a British Birth Cohort Study. J Am Geriatr Soc. 2018;66(5):916-923.
Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. Anticholinergic drug exposure and the risk of dementia. JAMA Intern Med. 2019;179(8):1084.
Bagdy GRP, Kecskeméti V, Chase D, Juhász G. Headache-type adverse effects of NO donors: vasodilation and beyond. Br J Pharmacol. 2010;160(1):20-35.
de Araújo CM, Barbosa IG, Lemos SMA, Domingues RB, Teixeira AL. Cognitive impairment in migraine: a systematic review. Dement Neuropsychol. 2012;6(2):74-79.
Barrington KJ. The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs. BMC Pediatr. 2001;6:1.
Cheng JYW, Chen RYL, Ko JSN, Ng EML. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis. Psychopharmacology. 2007;194(2):197-209.
Hutchinson AD, Hosking JR, Kichenadasse G, Mattiske JK, Wilson C. Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev. 2012;38(7):926-934.
Abdel-Rahman O, Fouad M. Risk of fatigue and hepatic and metabolic toxicities in patients with solid tumors treated with everolimus: a meta-analysis. Future Oncol. 2015;11(1):79-90.
Chen LC, Ashcroft DM. Meta-analysis of the efficacy and safety of zolmitriptan in the acute treatment of migraine. Headache. 2008;48(2):236-247.
Moga DC, Abner EL, Wu Q, Jicha GA. Bladder antimuscarinics and cognitive decline in elderly patients. Alzheimer's Dement. 2017;3(1):139-148.
Koppelmans V, Breteler MMB, Boogerd W, Seynaeve C, Gundy C, Schagen SB. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. J Clin Oncol. 2012;30(10):1080-1086.
National Institute for Health and Care Excellence (NICE). Adverse Reactions to Drugs. 2020. https://bnf.nice.org.uk/guidance/adverse-reactions-to-drugs.html. Accessed 9 March, 2020.
Tfelt-Hansen PC, Tfelt-Hansen J. Nitroglycerin headache and Nitroglycerin-induced primary headaches from 1846 and onwards: a historical overview and update. Headache. 2009;49:445-456.
Rossor M, Knapp M. Can we model a cognitive footprint of interventions and policies to help to meet the global challenge of dementia? Lancet. 2015;386(9997):1008-1010.
Ellingsen KM. Standardized assessment of cognitive development: instruments and issues. In: Garro A, ed. Early Childhood Assessment in School and Clinical Child Psychology. New York, NY: Springer Science+Business Media; 2016:25-49.
Addington-Hall J, Kalra L. Who should measure quality of life? BMJ. 2001;322(7299):1417-1420.
Cullen B, O'Neill B, Evans JJ, Coen RF, Lawlor BA. A review of screening tests for cognitive impairment. J Neurol Neurosurg Psychiatry. 2007;78(8):790-799.
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.
Steis MR, Schrauf RW. A review of translations and adaptations of the Mini-Mental State Examination in Languages other than English and Spanish. Res Gerontol Nurs. 2009;2(3):214-224.
Crum RM, Anthony JC, Bassett SS, Folstein MF. Population-based norms for the mini-mental state examination by age and educational level. JAMA. 1993;269(18):2386-2391.
Gluhm S, Goldstein J, Loc K, Colt A, Van Liew C, Corey-Bloom J. Cognitive performance on the mini-mental state examination and the montreal cognitive assessment across the healthy adult lifespan. Cogni Behav Neurol. 2013;26(1):1-5.
Tombaugh TN, McIntyre NJ. The mini-mental state examination: a comprehensive review. J Am Geriatr Soc. 1992;40:922-935.
Weiss BD, Reed R, Kligman EW, Abyad A. Literacy and performance on the mini-mental state examination. J Am Geriatr Soc. 1995;43(7):807-810.
Nasreddine ZS, Phillips NA, Bédirian V, et al. The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695-699.
Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141(11):1356-1364.
Mioshi E, Dawson K, Mitchell J, Arnold R, Hodges JR. The Addenbrooke's Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry. 2006;21:1078-1085.
Roth M, Tym E, Mountjoy CQ, et al. CAMDEX: a standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiatry. 1986;149:698-709.
Tariq SH, Tumosa N, Chibnall JT, Perry MH, Morley JE. Comparison of the Saint Louis University mental status examination and the mini-mental state examination for detecting dementia and mild neurocognitive disorder-A Pilot Study. Am J Geriatr Psychiatry. 2006;14(11):900-910.
Brodaty H, Pond D, Kemp NM, et al. The GPCOG: a new screening test for dementia designed for general practice. J Am Geriatr Soc. 2002;50(3):530-534.
Borson S, Scanlan J, Brush M, Vitaliano P, Dokmak A. The Mini-Cog: a cognitive 'vital signs' measure for dementia severity in multi-lingual elderly. Int J Geriatr Psychiatry. 2000;15:1021-1027.
Hodkinson HM. Evaluation of a mental test score for assessment of mental impairment in the elderly. Age Ageing. 2012;41(suppl_3):iii35-iii40.
Libert Y, Dubruille S, Borghgraef C, et al. Vulnerabilities in older patients when cancer treatment is initiated: does a cognitive impairment impact the two-year survival? PLoS ONE. 2016;11(8):e0159734.
Zheng T, Qin L, Chen B, et al. Association of plasma DPP4 activity with mild cognitive impairment in elderly patients with type 2 diabetes: results from the GDMD Study in China. Diabetes Care. 2016;39(9):1594-1601.
Wang C, An Y, Yu H, et al. Association between exposure to the Chinese famine in different stages of early life and decline in cognitive functioning in adulthood. Front Behav Neurosci. 2016;10:146.
Palanisamy A, Rajendran NN, Narmadha MP, Ganesvaran RA. Comparative assessment of Montreal Cognitive Assessment (MOCA) and Minimental State Examination (MMSE) in apolipoprotein E (APOE) ɛ4 allele carriers in epilepsy. Int J Epilepsy. 2016;3(1):7-11.
Wesnes KA, Harrison JE. The evaluation of cognitive function in the dementias: methodological and regulatory considerations. Dialogues Clin Neurosci. 2003;5(1):77-88.
Jitapunkul S, Pillay I, Ebrahim S. The abbreviated mental test: its use and validity. Age Ageing. 1991;20(5):332-336.
Keefe RSE, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The brief assessment of cognition in schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res. 2004;68(2):283-297.
Cholet J, Sauvaget A, Vanelle JM, et al. Using the Brief Assessment of Cognition in Schizophrenia (BACS) to assess cognitive impairment in older patients with schizophrenia and bipolar disorder. Bipolar Disord. 2014;16(3):326-336.
Neuchterlein KH, Green MF, Kern RS, et al. The MATRICS consensus cognitive battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008;165:203-213.
Yatham LN, Torres IJ, Malhi GS, et al. The International Society for Bipolar Disorders-Battery for Assessment of Neurocognition (ISBD-BANC). Bipolar Disord. 2010;12(4):351-363.
Lam RW, Kennedy SH, McIntyre RS, Khullar A. Cognitive dysfunction in major depressive disorder: effects on psychosocial functioning and implications for treatment. Can J Psychiatry. 2014;59(12):649-654.
Svendsen AM, Kessing LV, Munkholm K, Vinberg M, Miskowiak KW. Is there an association between subjective and objective measures of cognitive function in patients with affective disorders? Nord J Psychiatry. 2012;66(4):248-253.
Piaget J. The Origins of Intelligence in Children. New York, NY: International Universities Press; 1952.
Bayley N. Bayley Scales of Infant and Toddler Development III (screening test). San Antonio, TX: Pearson; 2005.
Conners C, Staff M. Conners' Continuous Performance Test II: Compure Program for Windows Technical Guide and Software Manual. North Tonawanda, NY: Multi-Health Systems. 2000.
Reitan RM, Wolfson D. The Haltstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation, 2nd edn. Tuscon, AZ: Neuropsychological Press; 1993.
Campbell JM, Brown RT, Cavanagh SE, Vess SF, Segall MJ. Evidence-based assessment of cognitive functioning in pediatric psychology. J Pediatr Psychol. 2008;33(9):999-1014.
Ord JS, Boettcher AC, Greve KJ, Bianchini KJ. Detection of malingering in mild traumatic brain injury with the Conners’ Continuous Performance Test-II. J Clin Exp Neuropsychol. 2010;32(4):380-387.
Tombaugh TN. Trail Making Test A and B: Normative data stratified by age and education. Arch Clin Neuropsychol. 2004;19(2):203-214.
The Medicines for Human Use (Clinical Trials) Regulations. London, UK: UK Government; 2004.
Ferrari A, Spaccapelo L, Gallesi D, Sternieri E. Focus on headache as an adverse reaction to drugs. J Headache Pain. 2009;10(4):235-239.
Ohishi A, Chisaki Y, Hira D, Nagasawa K, Terada T. Opioid analgesics increase incidence of somnolence and dizziness as adverse effects of pregabalin: a retrospective study. J Pharm Health Care Sci. 2015;1:30.
Wells RE, Kaptchuk TJ. To tell the truth, the whole truth, may do patients harm: the problem of the nocebo effect for informed consent. Am J Bioeth. 2012;12(3):22-29.
Planès S, Villier C, Mallaret M. The nocebo effect of drugs. Pharmacol Res Perspect. 2016;4(2):e00208.
Dhingra L, Ahmed E, Shin J, Scharaga E, Magun M. Cognitive effects and sedation. Pain Med. 2015;16(Suppl 1):S37-S43.
Deary IJ, Liewald D, Nissan J. A free, easy-to-use, computer-based simple and four-choice reaction time programme: the Deary-Liewald reaction time task. Behav Res Methods. 2011;43(1):258-268.
Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol. 1935;18(6):643-662.
Homack S, Riccio CA. A meta-analysis of the sensitivity and specificity of the Stroop Color and Word Test with children. Arch Clin Neuropsychol. 2004;19(6):725-743.
Spieler DH, Balota DA, Faust ME. Stroop performance in healthy younger and older adults and in individuals with dementia of the Alzheimer's type. J Exp Psychol Hum Percept Perform. 1996;22(2):461-479.
Ryan NM. A review on the efficacy and safety of gabapentin in the treatment of chronic cough. Expert Opin Pharmacother. 2015;16(1):135-145.